The Latest Cardiac and Vascular News
ATLANTA, April 30, 2020 /PRNewswire/ — First Quarter and Recent Business Highlights: Achieved total revenues of $66.4 million in the first quarter 2020 versus preliminary first quarter 2020 revenues of $65.5 million Total revenues decreased 2% and decreased 1% on a constant currency basis versus first quarter 2019 Excluding TMR, total revenues increased 1% and […]
Biomedical Company Hires Denver Agency for Strategic Guidance and Marketing Support DENVER–(BUSINESS WIRE)–Catalyst, a Denver marketing agency, today announced that they were selected by CryoLife, a biomedical company, for marketing services. The marketing services include design, content development and sales enablement tools creation. Headquartered in suburban Atlanta, Georgia, CryoLife is one of the […]
March 4, 2020 at 4:05 PM EST Newest Hybrid Stent Graft Offering Enhances Ease-of-Use ATLANTA, March 4, 2020 /PRNewswire/ — CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has received CE Mark for the E-vita Open NEO, a hybrid stent graft system for the treatment […]
ATLANTA, Feb. 27, 2020 /PRNewswire/ — CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today it has received CE Mark for the On-X Ascending Aortic Prosthesis (AAP), allowing resumed distribution in the European Union. The On-X AAP is indicated for the treatment of diseased, damaged or malfunctioning […]
Study Designed to Evaluate the Use of Apixaban in On-X Aortic Valve Patients ATLANTA, Dec. 23, 2019 /PRNewswire/ — CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has received authorization from the U.S. Food and Drug Administration (FDA) pursuant to an Investigational New […]
CryoLife Will Supply NeoPatch, a Chorioamniotic Membrane Tissue, to Misonix ATLANTA, Dec. 19, 2019 /PRNewswire/ — CryoLife, Inc. (“CryoLife”;NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has entered into an agreement whereby Misonix (NASDAQ: MSON) will have exclusive US commercialization rights for CryoLife’s NeoPatch product to […]
First Off-the-Shelf Thoraco-abdominal Stent Graft with Pre-Cannulated Inner Branch Technology ATLANTA, Dec. 2, 2019 /PRNewswire/ — CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has received CE Mark for the E-nside TAAA multibranch stent graft system for the endovascular treatment of thoraco-abdominal aneurysms. Approximately […]
Product Launch Anticipated in the First Quarter 2020 ATLANTA, Dec. 2, 2019 /PRNewswire/ — CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today it has received CE Mark for the E-nya thoracic stent graft system for the minimally invasive repair of lesions of the descending thoracic aorta, […]
ATLANTA, Oct. 30, 2019 /PRNewswire/ — Third Quarter and Recent Business Highlights: Total revenues were $67.9 million in the third quarter of 2019, reflecting year over year growth of 5% and a 6% increase on a non-GAAP constant currency basis, both compared to the third quarter of 2018 On-X® revenues increased 12%, and 12% on […]
Positions the Company for Accelerating Revenue and Non-GAAP Earnings Growth Over the Next Five Years Conference Call and Webcast Tomorrow, September 12, 2019 at 8:00 a.m. ET ATLANTA, Sept. 11, 2019 /PRNewswire/ — CryoLife, Inc. (“CryoLife”;NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has entered […]
